Increased expression of the progesterone receptor membrane component 1 (PGRMC1) has been linked to multiple cancers, including breast cancer. Despite being a regulatory receptor and a potential therapeutic target, the oncogenic potential of PGRMC1 has not been studied.
The impact of PGRMC1 on breast cancer growth and progression was studied following chemical inhibition and alteration of PGRMC1 expression, and evaluated by using online-based gene expression datasets of human breast cancer tissue. MTS, flow cytometry, qPCR, Western blotting, confocal microscopy and phosphoproteome analysis were performed.
We observed higher PGRMC1 levels in both ER-positive ZR-75-1 and TNBC MDA-MB-468 cells. Both chemical inhibition and silencing decreased cell proliferation, induced cell-cycle arrest, promoted apoptosis and reduced the migratory and invasive capabilities of ZR-75-1 and MDA-MB-468 cells. Further, phosphoproteome analysis demonstrated an overall decrease in activation of proteins involved in PI3K/AKT/mTOR and EGFR signalling pathways. In contrast, overexpression of PGRMC1 in non-malignant MCF10A cells resulted in increased cell proliferation, and enhanced activity of PI3K/AKT/mTOR and EGFR signalling pathways.
Our data demonstrate that PGRMC1 plays a prominent role in regulating the growth of cancer cells by altering the PI3K/AKT/mTOR and EGFR signalling mechanisms in both ER-positive and TNBC cells.
Subscribe to Journal
Get full journal access for 1 year
only $32.88 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A. & Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69, 7–34 (2019).
Spring, L. M., Gupta, A., Reynolds, K. L., Gadd, M. A., Ellisen, L. W., Isakoff, S. J. et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2, 1477–1486 (2016).
Burstein, H. J., Prestrud, A. A., Seidenfeld, J., Anderson, H., Buchholz, T. A., Davidson, N. E. et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J. Clin. Oncol. 28, 3784–3796 (2010).
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M. et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365, 1273–1283 (2011).
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E. & Gianni, L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol. 13, 674–690 (2016).
Chang, M. Tamoxifen resistance in breast cancer. Biomol. Ther. (Seoul.) 20, 256–267 (2012).
Rexer, B. N. & Arteaga, C. L. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit. Rev. Oncog. 17, 1–16 (2012).
Wein, L. & Loi, S. Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC). Breast 34, S27–S30 (2017).
Kabe, Y., Nakane, T., Koike, I., Yamamoto, T., Sugiura, Y., Harada, E. et al. Haem-dependent dimerization of PGRMC1/Sigma-2 receptor facilitates cancer proliferation and chemoresistance. Nat. Commun. 7, 11030 (2016).
Hughes, A. L., Powell, D. W., Bard, M., Eckstein, J., Barbuch, R., Link, A. J. et al. Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes. Cell Metab. 5, 143–149 (2007).
Peluso, J. J., Liu, X., Saunders, M. M., Claffey, K. P. & Phoenix, K. Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1. J. Clin. Endocrinol. Metab. 93, 1592–1599 (2008).
Mir, S. U., Ahmed, I. S., Arnold, S. & Craven, R. J. Elevated progesterone receptor membrane component 1/sigma-2 receptor levels in lung tumors and plasma from lung cancer patients. Int J. Cancer 131, E1–E9 (2012).
Craven, R. J. PGRMC1: a new biomarker for the estrogen receptor in breast cancer. Breast Cancer Res. 10, 113 (2008).
Ruan, X., Zhang, Y., Mueck, A. O., Willibald, M., Seeger, H., Fehm, T. et al. Increased expression of progesterone receptor membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer. Menopause 24, 203–209 (2017).
Crudden, G., Loesel, R. & Craven, R. J. Overexpression of the cytochrome p450 activator hpr6 (heme-1 domain protein/human progesterone receptor) in tumors. Tumour Biol. 26, 142–146 (2005).
Cahill, M. A., Jazayeri, J. A., Catalano, S. M., Toyokuni, S., Kovacevic, Z. & Richardson, D. R. The emerging role of progesterone receptor membrane component 1 (PGRMC1) in cancer biology. Biochim Biophys. Acta 1866, 339–349 (2016).
Ahmed, I. S., Rohe, H. J., Twist, K. E. & Craven, R. J. Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity. J. Biol. Chem. 285, 24775–24782 (2010).
Nakai, K., Hung, M. C. & Yamaguchi, H. A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am. J. Cancer Res 6, 1609–1623 (2016).
Mi, H., Muruganujan, A., Huang, X., Ebert, D., Mills, C., Guo, X. et al. Protocol Update for large-scale genome and gene function analysis with the PANTHER classification system (v.14.0). Nat. Protoc. 14, 703–721 (2019).
Oksvold, M. P., Thien, C. B., Widerberg, J., Chantry, A., Huitfeldt, H. S. & Langdon, W. Y. Serine mutations that abrogate ligand-induced ubiquitination and internalization of the EGF receptor do not affect c-Cbl association with the receptor. Oncogene 22, 8509–8518 (2003).
van Waarde, A., Rybczynska, A. A., Ramakrishnan, N. K., Ishiwata, K., Elsinga, P. H. & Dierckx, R. A. Potential applications for sigma receptor ligands in cancer diagnosis and therapy. Biochim Biophys. Acta 1848, 2703–2714 (2015).
Neubauer, H., Ma, Q., Zhou, J., Yu, Q., Ruan, X., Seeger, H. et al. Possible role of PGRMC1 in breast cancer development. Climacteric 16, 509–513 (2013).
Causey, M. W., Huston, L. J., Harold, D. M., Charaba, C. J., Ippolito, D. L., Hoffer, Z. S. et al. Transcriptional analysis of novel hormone receptors PGRMC1 and PGRMC2 as potential biomarkers of breast adenocarcinoma staging. J. Surg. Res. 171, 615–622 (2011).
Rohe, H. J., Ahmed, I. S., Twist, K. E. & Craven, R. J. PGRMC1 (progesterone receptor membrane component 1): a targetable protein with multiple functions in steroid signaling, P450 activation and drug binding. Pharm. Ther. 121, 14–19 (2009).
Clark, N. C., Friel, A. M., Pru, C. A., Zhang, L., Shioda, T., Rueda, B. R. et al. Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors. Cancer Biol. Ther. 17, 262–271 (2016).
Ahmed, I. S., Rohe, H. J., Twist, K. E., Mattingly, M. N. & Craven, R. J. Progesterone receptor membrane component 1 (Pgrmc1): a heme-1 domain protein that promotes tumorigenesis and is inhibited by a small molecule. J. Pharm. Exp. Ther. 333, 564–573 (2010).
Yoshitani, N., Satou, K., Saito, K., Suzuki, S., Hatanaka, H., Seki, M. et al. A structure-based strategy for discovery of small ligands binding to functionally unknown proteins: combination of in silico screening and surface plasmon resonance measurements. Proteomics 5, 1472–1480 (2005).
Will, E. A., Liu, X. & Peluso, J. J. AG 205, a progesterone receptor membrane component 1 antagonist, ablates progesterone’s ability to block oxidative stress-induced apoptosis of human granulosa/luteal cells†. Biol. Reprod. 96, 843–854 (2017).
Teakel, S. L., Ludescher, M., Thejer, B. M., Poschmann, G., Forwood, J. K., Neubauer, H. et al. Protein complexes including PGRMC1 and actin-associated proteins are disrupted by AG-205. Biochem Biophys. Res Commun. 524, 64–69 (2020).
Zhao, Y. & Ruan, X. Identification of PGRMC1 as a candidate oncogene for head and neck cancers and its involvement in metabolic activities. Front Bioeng. Biotechnol. 7, 438 (2019).
Sun, Q., Jackson, R. A., Ng, C., Guy, G. R. & Sivaraman, J. Additional serine/threonine phosphorylation reduces binding affinity but preserves interface topography of substrate proteins to the c-Cbl TKB domain. PLoS ONE 5, e12819 (2010).
Countaway, J. L., Nairn, A. C. & Davis, R. J. Mechanism of desensitization of the epidermal growth factor receptor protein-tyrosine kinase. J. Biol. Chem. 267, 1129–1140 (1992).
Feinmesser, R. L., Wicks, S. J., Taverner, C. J. & Chantry, A. Ca2+/calmodulin-dependent kinase II phosphorylates the epidermal growth factor receptor on multiple sites in the cytoplasmic tail and serine 744 within the kinase domain to regulate signal generation. J. Biol. Chem. 274, 16168–16173 (1999).
Shen, M., Jiang, Y. Z., Wei, Y., Ell, B., Sheng, X., Esposito, M. et al. Tinagl1 suppresses triple-negative breast cancer progression and metastasis by simultaneously inhibiting integrin/FAK and EGFR signaling. Cancer Cell. 35, 64–80 (2019). e7.
Nakai, K., Xia, W., Liao, H. W., Saito, M., Hung, M. C. & Yamaguchi, H. The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells. Breast Cancer 25, 74–80 (2018).
Majorini, M. T., Manenti, G., Mano, M., De Cecco, L., Conti, A., Pinciroli, P. et al. cIAP1 regulates the EGFR/Snai2 axis in triple-negative breast cancer cells. Cell Death Differ. 25, 2147–2164 (2018).
Saha Roy, S. & Vadlamudi, R. K. Role of estrogen receptor signaling in breast cancer metastasis. Int J. Breast Cancer 2012, 654698 (2012).
Daniel, A. R., Hagan, C. R. & Lange, C. A. Progesterone receptor action: defining a role in breast cancer.Expert Rev. Endocrinol. Metab. 6, 359–369 (2011).
Cui, C., Li, S. & Wu, D. Znhit1 inhibits breast cancer by up-regulating PTEN to deactivate the PI3K/Akt/mTOR pathway. Life Sci. 224, 204–211 (2019).
Lee, Y. R., Chen, M., Lee, J. D., Zhang, J., Lin, S. Y., Fu T. M. et al. Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. Science 364, eaau0159 (2019).
Lee, Y. R., Chen, M. & Pandolfi, P. P. The functions and regulation of the PTEN tumour suppressor: new modes and prospects. Nat. Rev. Mol. Cell Biol. 19, 547–562 (2018).
We thank the Texas Tech University Health Sciences Center El Paso for supporting this project.
Ethics approval and consent to participate
MCF12A, MCF10A, MCF7, T47D, ZR-75-1, MDA-MB-231 and MDA-MB-468 cell lines were acquired from the American Type Culture Collection (Manassas, VA, USA).
Consent to publish
All data generated or analysed during this study are included in this published article [and its Supplementary information files].
The authors declare no competing interests.
Breast Cancer Discretionary Fund from Texas Tech University Health Sciences Center El Paso.
Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Pedroza, D.A., Rajamanickam, V., Subramani, R. et al. Progesterone receptor membrane component 1 promotes the growth of breast cancers by altering the phosphoproteome and augmenting EGFR/PI3K/AKT signalling. Br J Cancer (2020). https://doi.org/10.1038/s41416-020-0992-6